JMJD3 mRNA expression escalated with tumor stage (p < 0.01) and was higher in recurred/progressed disease than disease free (p < 0.05) and also higher in dead patients than living patients (p < 0.05) (Fig. 1F–H). This evidence concerns the gene KDM6B and neoplasm.